Yi-Long Wu Selected Research

Yi-Long Wu Research Topics

Disease

198	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 11/2022 - 01/2005
105	Neoplasms (Cancer) 11/2022 - 09/2007
78	Lung Neoplasms (Lung Cancer) 01/2022 - 09/2007
27	Disease Progression 01/2022 - 10/2009
26	Neoplasm Metastasis (Metastasis) 01/2022 - 07/2005
23	Adenocarcinoma of Lung 01/2022 - 01/2012
15	Diarrhea 01/2022 - 09/2009
14	Brain Neoplasms (Brain Tumor) 11/2022 - 07/2015
14	Adenocarcinoma 11/2019 - 05/2007
13	Exanthema (Rash) 11/2018 - 11/2008
10	Nausea 01/2022 - 11/2011
10	Neutropenia 10/2018 - 11/2008
9	Vomiting 01/2022 - 02/2014
8	Carcinoma (Carcinomatosis) 12/2020 - 01/2006
7	Fatigue 01/2018 - 10/2009
5	Stomatitis 02/2021 - 02/2014
5	Acne Vulgaris 01/2018 - 11/2008
4	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2020 - 01/2016
4	Vision Disorders (Hemeralopia) 10/2018 - 06/2013
4	Urinary Bladder Neoplasms (Bladder Cancer) 12/2015 - 03/2008
3	Pleural Effusion (Pleural Effusions) 01/2022 - 01/2020
3	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2022 - 09/2014
3	Edema (Dropsy) 01/2022 - 12/2014
3	Anemia 03/2021 - 10/2018
3	Paronychia 02/2021 - 02/2015
3	Dermatitis 02/2021 - 11/2017
3	Leukopenia 10/2018 - 09/2010
3	Alopecia (Baldness) 06/2013 - 11/2008
2	Pneumonia (Pneumonitis) 01/2022 - 11/2017
2	Sarcoma (Soft Tissue Sarcoma) 10/2021 - 07/2014
2	COVID-19 01/2021 - 01/2020
2	Genetic Predisposition to Disease (Genetic Predisposition) 01/2021 - 02/2016
2	Breast Neoplasms (Breast Cancer) 10/2020 - 02/2013
2	Infections 09/2020 - 01/2020

Drug/Important Bio-Agent (IBA)

91	ErbB Receptors (EGF Receptor)IBA 11/2022 - 01/2006
73	Tyrosine Kinase InhibitorsIBA 11/2022 - 09/2007
42	Gefitinib (Iressa)FDA Link 11/2022 - 05/2007
25	PlatinumIBA 12/2021 - 11/2008
21	Biomarkers (Surrogate Marker)IBA 11/2022 - 09/2007
20	Cisplatin (Platino)FDA LinkGeneric 12/2021 - 07/2013
19	CrizotinibIBA 11/2022 - 06/2013
18	osimertinibIBA 03/2022 - 01/2017
18	Pemetrexed (MTA)FDA Link 10/2021 - 10/2009
18	Carboplatin (JM8)FDA LinkGeneric 01/2021 - 01/2005
17	Proteins (Proteins, Gene)FDA Link 12/2021 - 06/2004
16	AfatinibIBA 04/2022 - 02/2014
14	Pharmaceutical PreparationsIBA 01/2022 - 10/2009
14	Anaplastic Lymphoma KinaseIBA 11/2021 - 03/2014
13	Immune Checkpoint InhibitorsIBA 11/2022 - 01/2017
13	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2021 - 10/2009
13	Gemcitabine FDA Link 01/2019 - 03/2010
12	Paclitaxel (Taxol)FDA LinkGeneric 01/2021 - 09/2009
11	B7-H1 AntigenIBA 01/2022 - 11/2018
11	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 05/2009
10	Alanine Transaminase (SGPT)IBA 03/2021 - 08/2011
9	Messenger RNA (mRNA)IBA 01/2022 - 09/2007
8	dacomitinibIBA 03/2021 - 11/2017
7	Docetaxel (Taxotere)FDA Link 12/2021 - 11/2008
6	LigandsIBA 01/2022 - 04/2016
6	pembrolizumabIBA 08/2021 - 12/2017
6	Aspartate Aminotransferases (Aspartate Transaminase)IBA 03/2021 - 11/2016
6	Phosphotransferases (Kinase)IBA 01/2017 - 09/2007
5	MicroRNAs (MicroRNA)IBA 01/2022 - 03/2016
5	Circulating Tumor DNAIBA 01/2022 - 12/2015
5	Bevacizumab (Avastin)FDA Link 01/2021 - 06/2012
4	Cell-Free Nucleic AcidsIBA 01/2022 - 01/2016
3	T-Cell Antigen Receptors (T-Cell Receptor)IBA 11/2022 - 01/2020
3	durvalumabIBA 01/2022 - 10/2020
3	Biological ProductsIBA 01/2022 - 03/2015
3	AntibodiesIBA 01/2022 - 01/2021
3	NivolumabIBA 12/2021 - 01/2019
3	icotinibIBA 12/2021 - 09/2013
3	ceritinibIBA 03/2021 - 01/2017
3	Vinorelbine (Navelbine)FDA LinkGeneric 01/2021 - 01/2018
3	Antineoplastic Agents (Antineoplastics)IBA 01/2021 - 10/2009
3	Etoposide (VP 16)FDA LinkGeneric 10/2019 - 11/2016
3	VaccinesIBA 10/2011 - 06/2004
2	RNA (Ribonucleic Acid)IBA 01/2022 - 01/2009
2	abivertinibIBA 01/2022 - 05/2019
2	Irinotecan (Camptosar)FDA LinkGeneric 12/2021 - 09/2010
2	Phosphoric Monoester Hydrolases (Phosphatases)IBA 10/2021 - 07/2014
2	capmatinibIBA 04/2021 - 11/2018
2	Coal (Coals)IBA 01/2021 - 03/2015
2	Coloring Agents (Dyes)IBA 01/2021 - 10/2020
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2021 - 06/2012
2	tislelizumabIBA 12/2020 - 01/2020
2	ORALIT (ORS)IBA 01/2020 - 10/2012
2	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2020 - 11/2011

Therapy/Procedure

71	Therapeutics 10/2022 - 05/2007
67	Drug Therapy (Chemotherapy) 11/2022 - 07/2005
18	Immunotherapy 01/2022 - 01/2009
8	Chemoradiotherapy 01/2022 - 08/2015
8	Neoadjuvant Therapy 01/2021 - 07/2005
6	Precision Medicine 01/2019 - 12/2009
5	Radiotherapy 10/2020 - 11/2011
3	Adjuvant Chemotherapy 01/2022 - 01/2017
3	Consolidation Chemotherapy 10/2019 - 08/2015
3	Lymph Node Excision (Lymph Node Dissection) 10/2017 - 08/2016
2	Drug Tapering 01/2022 - 03/2021
2	Aftercare (After-Treatment) 01/2021 - 06/2015